137 related articles for article (PubMed ID: 37741716)
1. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
Wolf J; Souquet PJ; Goto K; Cortot A; Baik C; Heist R; Kim TM; Han JY; Neal JW; Mansfield AS; Gilloteau I; Nwana N; Waldron-Lynch M; Davis KL; Giovannini M; Awad MM
Clin Lung Cancer; 2023 Nov; 24(7):641-650.e2. PubMed ID: 37741716
[TBL] [Abstract][Full Text] [Related]
2. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
3. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
[TBL] [Abstract][Full Text] [Related]
4. Real-world insights into patients with advanced NSCLC and MET alterations.
Bittoni M; Yang JC; Shih JY; Peled N; Smit EF; Camidge DR; Arasada RR; Oksen D; Boutmy E; Stroh C; Johne A; Carbone DP; Paik PK
Lung Cancer; 2021 Sep; 159():96-106. PubMed ID: 34320421
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
[No Abstract] [Full Text] [Related]
6. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
7. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
8. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
10. Capmatinib in
Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
[TBL] [Abstract][Full Text] [Related]
11. Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.
Skribek M; Brunnström H; Oskarsdottir G; Portu Grivé M; Aricak O; Planck M; Jatta K; Naserhojati H; Haglund de Flon F; Ekman S
Acta Oncol; 2023 Dec; 62(12):1808-1814. PubMed ID: 37897706
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
Lee JK; Madison R; Classon A; Gjoerup O; Rosenzweig M; Frampton GM; Alexander BM; Oxnard GR; Venstrom JM; Awad MM; Schrock AB
JCO Precis Oncol; 2021; 5():. PubMed ID: 34476332
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
14. MET alterations in NSCLC-Current Perspectives and Future Challenges.
Remon J; Hendriks LEL; Mountzios G; García-Campelo R; Saw SPL; Uprety D; Recondo G; Villacampa G; Reck M
J Thorac Oncol; 2023 Apr; 18(4):419-435. PubMed ID: 36441095
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
17. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib in
Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
Pruis MA; Krebs MG; Plummer R; De Vos F; Angevin E; Prenen H; Forster MD; Clack G; Van der Aa A; Tjwa M; Jansen E; Perera T; Lolkema MP
Oncologist; 2023 Dec; 28(12):e1248-e1258. PubMed ID: 37260332
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
